Findings

What do systematic reviews say?

2 questions · 2 findings · 1 reviews · Colorectal

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 2 · 100%High 0 · 0%

Progression‐free survival · people with metastatic colorectal cancer ‐ extended RAS WT

The intervention probably leads to lower progression‐free survival (moderate certainty).

1 finding from 1 review

Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer 2017 · Cochrane Headline outcomes only
HR 0.6 [0.48, 0.75]
6 studies · 1237 participants
Moderate

Progression‐free survival · people with metastatic colorectal cancer ‐ extended RAS MT

The intervention showed no clear difference in progression‐free survival (moderate certainty).

1 finding from 1 review

Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer 2017 · Cochrane Headline outcomes only
HR 1.13 [0.93, 1.36]
6 studies · 2023 participants
Moderate